Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Mendelian Disorders Testing market is experiencing noteworthy trends that are reshaping the landscape of genetic diagnostics. One prominent trend is the increasing adoption of genetic testing for Mendelian disorders, driven by advancements in DNA sequencing technologies. The ability to rapidly and cost-effectively sequence an individual's entire genome or specific gene regions has revolutionized the diagnosis of Mendelian disorders, providing healthcare professionals with unprecedented insights into the genetic basis of these conditions.
Technological advancements, particularly in next-generation sequencing (NGS), are playing a pivotal role in shaping market trends. NGS allows for high-throughput sequencing, enabling the simultaneous analysis of multiple genes associated with Mendelian disorders. This has significantly reduced the time and cost involved in genetic testing, making it more accessible to a broader population. The trend towards more efficient and affordable testing methods is facilitating widespread adoption, leading to earlier and more accurate diagnoses of Mendelian disorders.
Another key trend is the expanding scope of Mendelian disorders testing beyond research settings to routine clinical practice. As the clinical utility and reliability of genetic testing have improved, healthcare providers are increasingly integrating genetic testing into their diagnostic workflows. This trend is transforming the standard of care for patients with suspected Mendelian disorders, allowing for personalized treatment plans based on the specific genetic mutations identified through testing.
Furthermore, the market is witnessing a growing emphasis on comprehensive genetic testing panels that cover a wide range of Mendelian disorders. These panels, which include hundreds or even thousands of genes associated with various genetic conditions, provide a more holistic approach to genetic testing. Healthcare professionals can leverage these panels to simultaneously assess a patient's risk for multiple Mendelian disorders, streamlining the diagnostic process and optimizing the use of genetic information in clinical decision-making.
The rise of direct-to-consumer genetic testing services is another significant trend in the Mendelian Disorders Testing market. Increasing consumer awareness and interest in their genetic makeup have led to the popularity of at-home DNA testing kits. While these services offer insights into ancestry and traits, they also provide information about potential genetic predispositions to certain Mendelian disorders. This trend is contributing to the democratization of genetic information, empowering individuals to take proactive measures for their health and facilitating the identification of potential genetic risks.
Collaboration and partnerships between genetic testing companies, healthcare providers, and pharmaceutical firms are also shaping market trends. These collaborations aim to enhance the integration of genetic testing results into patient care, facilitate research on Mendelian disorders, and accelerate the development of targeted therapies. The synergies created by these partnerships contribute to a more comprehensive and patient-centric approach to managing Mendelian disorders.
Despite the positive trends, challenges such as ethical considerations, data privacy concerns, and the interpretation of genetic variants remain important considerations in the Mendelian Disorders Testing market. Striking a balance between providing valuable genetic information and ensuring the responsible use of that information is crucial for maintaining public trust and advancing the field.
Mendelian Disorders Testing Market Highlights:
Global Mendelian Disorders Testing Market Overview
Mendelian Disorders Testing Market Size was valued at USD 0.4 billion in 2023. The Mendelian Disorders Testing Market industry is projected to grow from USD 0.43 billion in 2024 to USD 0.96 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.54% during the forecast period (2024 - 2032). Genetic testing involves the use of laboratory methods to study the genes inherited from mother or father. These tests may be used to identify increased risks of health problems, to diagnose the mutations in the genes, to choose treatments, or to assess responses to treatment.
Mendelian disorders also known as monogenic diseases arise due to the modifications in a single gene occurring in all cells of the body. Currently, it is estimated that over 10,000 of human diseases are known to be monogenic. These disorders are responsible for a heavy loss of life. The global prevalence of monogenic diseases at birth is approximately 10 in every 1000 infants.
The Mendelian disorders are caused by a single mutated gene which can be present on single or both chromosomes. Both females and males are equally affected by this disorder. Sickle cell anemia, Cystic fibrosis, Tay-Sachs disease, SCID, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassemia, polycystic kidney disorder, and familial hypercholesterolemia are some of the common monogenic disorders. Nowadays, there are several tests performed to treat monogenic disorders such as diagnostic testing, carrier testing, predictive & pre-symptomatic testing, prenatal testing and new-born screening.
The carrier testing is a type of genetic testing that is used to determine a carrier person for monogenic disorders. Having said that, more and more genetic tests are being developed for a lot of other genetic disorders. Oncology segment has been the major focus area of the companies developing these tests as the large pool of population is affected by this fatal disease. The continuous rise in the prevalence of the genetic disorders has boosted the growth of the genetic testing market.
Intended Audience
- Mendelian Disorders Test Kit Suppliers
- Mendelian Disorders Test Kit Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Research Methodology
- Sources: Annual reports, Press release, White paper, and Company presentation
- Description: Mendelian disorders testing Market, Mendelian disorders testing, Mendelian disorders testing Market in Europe, Mendelian disorders testing Market in Asia Pacific, Mendelian disorders testing Market in the Middle East
Mendelian Disorders Testing Market Segmentation
The Mendelian disorders testing market is segmented on the basis of test type, disorder type, and end-user.
Mendelian Disorders Testing Type Insights
On the basis of the test type, the Mendelian disorders testing market is segmented into carrier testing, diagnostic testing, new-born screening, predictive & pre-symptomatic testing, prenatal testing, and others
Mendelian Disorders Testing Disorder Type Insights
On the basis of the disorder type, the mendelian disorders testing market is segmented into cystic fibrosis, sickle cell anemia, severe combined immunodeficiency (SCID), Tay-Sachs disorder, polycystic kidney disorder, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassemia, familial hypercholesterolemia, and others
Mendelian Disorders Testing End-User Insights
On the basis of the end user, the mendelian disorders testing market is segmented into hospitals, ambulatory surgical centers (ASCs), and specialized clinics.
Mendelian Disorders Testing Regional Insights
The Mendelian disorders testing market is segmented as the Americas, Europe, Asia Pacific and the Middle East and Africa.
The Americas is projected to hold the largest share of the mendelian disorders testing market. The unique opportunity drives the Mendelian disorders testing the market, and the focused issues stress on the need for more research on monogenic disorder tests. In the United States, sickle cell anemia affects around 72,000 people, the majority of this population have their ancestors from Africa. All the factors above are anticipated to boost the market growth in the U.S. and ensure its dominance over the forecast period.
Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. About 6,000 people are affected with hemophilia in the UK. Moreover, about 5400 people in the U.K with hemophilia A and about 1100 with hemophilia B.
The market in the Asia Pacific is expected to witness the fastest growth rate due to increasing prevalence of monogenic disorders throughout the globe, which will boost the growth of the monogenetic disorders testing market.
The Middle East and Africa are also expected to show healthy growth in the coming five years.
Mendelian Disorders Testing Market Key Players
The existing players are strengthening their foothold in the industry by introducing technologically advanced products. Regulatory bodies such as the US FDA and the European CE mark, although stringent, are approving equipment that fulfills all clinical data requirement and other safety criteria.
- Celera Group (U.S.)
- Abbott Laboratories (U.S.)
- ELITechGroup (France)
- Quest Diagnostics (U.S.)
- AutoGenomics (U.S.)
- PerkinElmer Inc. (U.S.)
- Roche Diagnostics (Switzerland)
- Bio-Rad Laboratories, Inc. (U.S.)
- Applied Biosystems Inc. (U.S.)
- Transgenomic Inc. (U.S.)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
